A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

March 31, 2019

Conditions
Breast CancerBreast CarcinomaBreast Tumors
Interventions
DRUG

Letrozole

DRUG

palbociclib

Trial Locations (52)

15215

Allegheny General Hospital, Pittsburgh

15232

University of Pittsburgh, Pittsburgh

17050

Pinnacle Health Ortenzio Cancer Center, Mechanicsburg

22911

Sentara Martha Jefferson Hospital-Phillips Family Cancer Center, Charlottesville

23298

Virginia Commonwealth University, Richmond

26506

West Virginia University, Morgantown

28806

Hope Women's Cancer Centers, Asheville

33136

University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center, Miami

40202

Norton Healthcare Pavillion, Louisville

40207

Norton Cancer Institute - Suburban, Norton Medical Plaza II, Louisville

40241

Norton Cancer Institute - Brownsboro Medical Plaza I, Louisville

55416

Metro-Minnesota CCOP, Saint Louis Park

62526

Cancer Care Specialists of Central Illinois, Decatur

77030

Baylor College of Medicine, Houston

79410

Joe Arrington Cancer Research and Treatment Center, Lubbock

90806

Long Beach Memorial Medical Center-Todd Cancer Institute, Long Beach

97213

Providence Oncology and Hematology Clinic, Portland

98104

Swedish Cancer Institute, Seattle

02905

Women and Infants Hospital of Rhode Island, Providence

H2W-1T8

Centre Hospitalier de l'Universite de Montreal, Montreal

H3T 1E2

Jewish General Hospital, Montreal

H4A 3J1

McGill University Health Center, Montreal

G1S 4L8

CHU de Quebec - Universite Laval, Québec

MK6 5LD

Milton Keynes Hospital, Milton Keynes

PE29 6NT

Hinchingbrooke Hospital, Huntingdon

TR1 3LQ

Royal Cornwall Hospital, Treliske, Truro

EX2 5DW

Royal Devon and Exeter Hospital, Exeter

BN2 5BE

Royal Sussex County Hospital, Brighton

SS0 0RY

Southend Hospital, Westcliff-on-Sea

DA2 8DA

Darent Valley Hospital, Dartford

ME16 9QQ

Maidstone Hospital, Maidstone

L7 8XP

Royal Liverpool University Hospital, Liverpool

NR31 6LA

James Paget University Hospital, Great Yarmouth

TA1 5DA

Musgrove Park Hospital, Taunton

BS23 4TQ

Weston General Hospital, Weston-super-Mare

SM2 5PT

The Royal Marsden Hospital, Sutton

SP2 8BJ

Salisbury Hospital, Salisbury

DY11 6RJ

Kidderminster Hospital, Kidderminster

B98 7UB

Alexandra Hospital, Redditch

WR5 1DD

Worcestershire Royal Hospital, Worcester

BT9 7AB

Belfast City Hospital, Belfast

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

EH4 2XU

Western General Hospital (Edinburgh Cancer Centre), Edinburgh

LS9 7TF

St James' University Hospital, Leeds

EN5 3DJ

Barnet Hospital, London

N19 5NF

Whittington Hospital, London

NW1 2BU

University College London Hospitals, London

SW3 6JJ

The Royal Marsden Hospital, London

W8 6RF

Charing Cross Hospital, London

NG5 1PB

Nottingham University Hospitals NHS Trust, City Campus, Nottingham

PL6 8DH

Derriford Hospital, Plymouth

SA2 8QA

Singleton Hospital, Swansea

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Royal Marsden NHS Foundation Trust

OTHER

collaborator

Institute of Cancer Research, United Kingdom

OTHER

lead

NSABP Foundation Inc

NETWORK

NCT02296801 - A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer | Biotech Hunter | Biotech Hunter